Physician

Garrie J. Haas, MD

According to 2025 Medicare claims, Garrie Haas, MD (NPI: 1104858018) practices advanced heart failure and transplant cardiology in the Columbus, OH market, with the plurality of this provider's patient population coming from Franklin, OH. This provider's primary affiliated billing organization is OSU INTERNAL MEDICINE, LLC (NPI: 1740231448; TIN: 311369596) and primary practice location at 43210-1240. Haas is affiliated with the Main Street Rural Health Sycamore ACO LLC (ACO ID: A5403) and CVS ACO (ACO ID: A5407), participating under the MSSP model.

Haas' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,425 traditional Medicare patients, billed 2,107 HCPCS/CPT codes, and received $50,304 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 3,237 prescription claims across 326 beneficiaries totaling $807,863 in drug costs, led by Entresto (Sacubitril/Valsartan). DME data shows 319 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $73,271 to $807,863. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $26,786 to $10,351.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,763	2,534	$53,019
2016	1,714	2,283	$54,399
2017	2,229	3,209	$65,626
2018	1,731	2,471	$59,344
2019	1,391	2,102	$65,888
2020	1,060	1,497	$47,571
2021	1,840	2,729	$56,015
2022	1,693	2,574	$60,254
2023	1,380	2,015	$48,715
2024	1,425	2,107	$50,304

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	179	2,073	$73,271
2016	189	2,038	$66,123
2017	189	1,807	$92,212
2018	196	1,738	$117,679
2019	207	1,893	$195,347
2020	206	1,916	$247,895
2021	222	2,053	$329,325
2022	259	2,390	$506,874
2023	306	2,990	$766,257
2024	326	3,237	$807,863

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	75	$38,008
2016	N/R	223	$68,438
2017	N/R	33	$1,584
2018	N/R	N/R	N/R
2019	N/R	550	$34,556
2020	N/R	308	$13,774
2021	N/R	196	$7,007
2022	39	319	$8,168
2023	63	393	$8,410
2024	56	319	$6,373

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	54	60	$101
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	43	110	$86
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	77	99	$61
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	50	50	$45
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	1,228	1,590	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Entresto	Sacubitril/Valsartan	210	13,135	$280,641
Farxiga	Dapagliflozin Propanediol	140	8,280	$148,262
Eliquis	Apixaban	118	6,518	$123,964
Jardiance	Empagliflozin	96	4,950	$94,756
Xarelto	Rivaroxaban	31	1,980	$34,673

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7517	Mycophenolate mofetil, oral, 250 mg	N	12	73	$1,887
J7507	Tacrolimus, immediate release, oral, 1 mg	N	14	79	$1,434
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	14	74	$1,299
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	16	81	$1,204
J7520	Sirolimus, oral, 1 mg	N	N/R	12	$550

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Garrie J. Haas, MD?

Tedicare shows public-source Medicare data for Garrie J. Haas, MD (NPI 1104858018), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Garrie J. Haas, MD have ACO affiliation data?

Garrie J. Haas, MD is shown with ACO affiliation data for Main Street Rural Health Sycamore ACO LLC (MSSP, ACO ID A5403) and CVS ACO (MSSP, ACO ID A5407).

What billing organization is linked to Garrie J. Haas, MD?

Garrie J. Haas, MD is linked to OSU INTERNAL MEDICINE, LLC (billing NPI 1740231448) in the available physician profile data.

Does Garrie J. Haas, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.